EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation

Samira Escopy, Elliot L Chaikof

Blood Vessels, Thrombosis & Hemostasis · 2024-09 · 1 (3) · 100015

DOI: 10.1016/j.bvth.2024.100015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2024-09. Verfasst von Samira Escopy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK, NIGMS, National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

P-selectin is a membrane glycoprotein and a member of the selectin family of cell adhesion molecules. It is prestored in α-granules of platelets and Weibel-Palade bodies of endothelial cells and is rapidly expressed on their surfaces upon activation during the course of an inflammatory response. Although a critical component of the innate immune system, the interaction of P-selectin with its cognate ligand, P-selectin glycoprotein ligand 1 (PSGL-1) may mediate maladaptive events central to the pathophysiology of venous thromboembolism, cardiovascular disease, stroke, metabolic syndrome, and sickle cell disease, among other disorders. As a consequence, a growing understanding of the significance of P-selectin and PSGL-1 in human disease has motivated the design of inhibitors that target the P-selectin/PSGL-1 pathway. Herein, we review the development and evaluation of both biologic and small-molecule inhibitors, including preclinical studies and clinical trials that have evaluated therapeutic potential of these agents for a variety of diseases linked to dysregulated inflammatory and thrombotic responses.

Autor:innen und Institutionen

  • Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Wyss Institute of Biologically Inspired Engineering, Harvard University, Boston, MA.
  • Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA.

Förderung

  • NIDDK
  • NIGMS
  • National Institutes of Health
  • NHLBI
  • Harvard Medical School

Zitieren

APA

Escopy, S., & Chaikof, E. L. (2024). Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation. Blood Vessels, Thrombosis & Hemostasis, 1(3), 100015. https://doi.org/10.1016/j.bvth.2024.100015

Vancouver

Escopy S, Chaikof EL. Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation. Blood Vessels, Thrombosis & Hemostasis. 2024;1(3):100015. doi:10.1016/j.bvth.2024.100015

BibTeX
@article{Escopy2024,
  author = {Escopy, Samira and Chaikof, Elliot L},
  title = {Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation},
  journal = {Blood Vessels, Thrombosis & Hemostasis},
  year = {2024},
  volume = {1},
  number = {3},
  pages = {100015},
  doi = {10.1016/j.bvth.2024.100015}
}
Kostenlos starten →